136 related articles for article (PubMed ID: 30597277)
1. Effect of CYP3A4, CYP3A5, and ABCB1 Polymorphisms on Intravenous Tacrolimus Exposure and Adverse Events in Adult Allogeneic Stem Cell Transplant Patients.
Hamadeh IS; Zhang Q; Steuerwald N; Hamilton A; Druhan LJ; McSwain M; Diez Y; Rusin S; Han Y; Symanowski J; Gerber J; Grunwald MR; Ghosh N; Plesca D; Arnall J; Trivedi J; Avalos B; Copelan E; Patel JN
Biol Blood Marrow Transplant; 2019 Apr; 25(4):656-663. PubMed ID: 30597277
[TBL] [Abstract][Full Text] [Related]
2. Tacrolimus concentrations in relation to CYP3A and ABCB1 polymorphisms among solid organ transplant recipients in Korea.
Jun KR; Lee W; Jang MS; Chun S; Song GW; Park KT; Lee SG; Han DJ; Kang C; Cho DY; Kim JQ; Min WK
Transplantation; 2009 Apr; 87(8):1225-31. PubMed ID: 19384171
[TBL] [Abstract][Full Text] [Related]
3. Influence of Germline Genetics on Tacrolimus Pharmacokinetics and Pharmacodynamics in Allogeneic Hematopoietic Stem Cell Transplant Patients.
Zhu J; Patel T; Miller JA; Torrice CD; Aggarwal M; Sketch MR; Alexander MD; Armistead PM; Coghill JM; Grgic T; Jamieson KJ; Ptachcinski JR; Riches ML; Serody JS; Schmitz JL; Shaw JR; Shea TC; Suzuki O; Vincent BG; Wood WA; Rao KV; Wiltshire T; Weimer ET; Crona DJ
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013193
[TBL] [Abstract][Full Text] [Related]
4. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation.
Turolo S; Tirelli AS; Ferraresso M; Ghio L; Belingheri M; Groppali E; Torresani E; Edefonti A
Pharmacol Rep; 2010; 62(6):1159-69. PubMed ID: 21273673
[TBL] [Abstract][Full Text] [Related]
5. Association between
Ho TT; Perkins JB; Gonzalez R; Hicks JK; Martinez RA; Duranceau K; North B; Kim J; Teer JK; Yao J; Yoder SJ; Nishihori T; Bejanyan N; Pidala J; Elmariah H
Pharmacogenomics; 2024 Jan; 25(1):29-40. PubMed ID: 38189154
[No Abstract] [Full Text] [Related]
6. Impact of Pharmacogenetics on Intravenous Tacrolimus Exposure and Conversions to Oral Therapy.
Pasternak AL; Marcath LA; Li Y; Nguyen V; Gersch CL; Rae JM; Frame D; Scappaticci G; Kidwell KM; Hertz DL
Transplant Cell Ther; 2022 Jan; 28(1):19.e1-19.e7. PubMed ID: 34583027
[TBL] [Abstract][Full Text] [Related]
7. Long-Term Influence of CYP3A5, CYP3A4, ABCB1, and NR1I2 Polymorphisms on Tacrolimus Concentration in Chinese Renal Transplant Recipients.
Liu F; Ou YM; Yu AR; Xiong L; Xin HW
Genet Test Mol Biomarkers; 2017 Nov; 21(11):663-673. PubMed ID: 28945481
[TBL] [Abstract][Full Text] [Related]
8. CYP3A and ABCB1 genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tacrolimus and its metabolites (M-I and M-III).
Yoon SH; Cho JH; Kwon O; Choi JY; Park SH; Kim YL; Yoon YR; Won DI; Kim CD
Transplantation; 2013 Mar; 95(6):828-34. PubMed ID: 23364483
[TBL] [Abstract][Full Text] [Related]
9. Influence of the CYP3A4/5 genetic score and ABCB1 polymorphisms on tacrolimus exposure and renal function in Brazilian kidney transplant patients.
Genvigir FD; Salgado PC; Felipe CR; Luo EY; Alves C; Cerda A; Tedesco-Silva H; Medina-Pestana JO; Oliveira N; Rodrigues AC; Doi SQ; Hirata MH; Hirata RD
Pharmacogenet Genomics; 2016 Oct; 26(10):462-72. PubMed ID: 27434656
[TBL] [Abstract][Full Text] [Related]
10. A Markov chain model to evaluate the effect of CYP3A5 and ABCB1 polymorphisms on adverse events associated with tacrolimus in pediatric renal transplantation.
Sy SK; Heuberger J; Shilbayeh S; Conrado DJ; Derendorf H
AAPS J; 2013 Oct; 15(4):1189-99. PubMed ID: 23990505
[TBL] [Abstract][Full Text] [Related]
11. Influence of CYP3A4, CYP3A5 and MDR-1 polymorphisms on tacrolimus pharmacokinetics and early renal dysfunction in liver transplant recipients.
Shi Y; Li Y; Tang J; Zhang J; Zou Y; Cai B; Wang L
Gene; 2013 Jan; 512(2):226-31. PubMed ID: 23107770
[TBL] [Abstract][Full Text] [Related]
12. Effect of CYP3A5, CYP3A4, and ABCB1 genotypes as determinants of tacrolimus dose and clinical outcomes after heart transplantation.
Díaz-Molina B; Tavira B; Lambert JL; Bernardo MJ; Alvarez V; Coto E
Transplant Proc; 2012 Nov; 44(9):2635-8. PubMed ID: 23146479
[TBL] [Abstract][Full Text] [Related]
13. CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.
Deininger KM; Vu A; Page RL; Ambardekar AV; Lindenfeld J; Aquilante CL
Clin Transplant; 2016 Sep; 30(9):1074-81. PubMed ID: 27314545
[TBL] [Abstract][Full Text] [Related]
14. Influence of ABCB1, CYP3A4*18B and CYP3A5*3 polymorphisms on cyclosporine A pharmacokinetics in bone marrow transplant recipients.
Qiu F; He XJ; Sun YX; Li-Ling J; Zhao LM
Pharmacol Rep; 2011; 63(3):815-25. PubMed ID: 21857093
[TBL] [Abstract][Full Text] [Related]
15. Impact of genetic polymorphisms on tacrolimus pharmacokinetics and the clinical outcome of renal transplantation.
Gervasini G; Garcia M; Macias RM; Cubero JJ; Caravaca F; Benitez J
Transpl Int; 2012 Apr; 25(4):471-80. PubMed ID: 22369694
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II.
Staatz CE; Goodman LK; Tett SE
Clin Pharmacokinet; 2010 Apr; 49(4):207-21. PubMed ID: 20214406
[TBL] [Abstract][Full Text] [Related]
17. Association of CYP3A5, CYP2C8, and ABCB1 Polymorphisms With Early Renal Injury in Chinese Liver Transplant Recipients Receiving Tacrolimus.
Deng R; Liao Y; Li Y; Tang J
Transplant Proc; 2018 Dec; 50(10):3258-3265. PubMed ID: 30577195
[TBL] [Abstract][Full Text] [Related]
18. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients.
Kuypers DR; de Jonge H; Naesens M; Lerut E; Verbeke K; Vanrenterghem Y
Clin Pharmacol Ther; 2007 Dec; 82(6):711-25. PubMed ID: 17495880
[TBL] [Abstract][Full Text] [Related]
19. Relationship between mRNA expression levels of CYP3A4, CYP3A5 and SXR in peripheral mononuclear blood cells and aging in young kidney transplant recipients under tacrolimus treatment.
Ferraresso M; Turolo S; Belingheri M; Tirelli AS; Cortinovis I; Milani S; Edefonti A; Ghio L
Pharmacogenomics; 2015; 16(5):483-91. PubMed ID: 25916520
[TBL] [Abstract][Full Text] [Related]
20. CYP3A7, CYP3A5, CYP3A4, and ABCB1 genetic polymorphisms, cyclosporine concentration, and dose requirement in transplant recipients.
Crettol S; Venetz JP; Fontana M; Aubert JD; Pascual M; Eap CB
Ther Drug Monit; 2008 Dec; 30(6):689-99. PubMed ID: 18978522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
